The CEO of South African pharmaceutical company Biovac Institute has said that the company is aiming to start production of the Pfizer (NYSE:PFE)/ BioNTech (Nasdaq:BNTX) mRNA COVID-19 vaccine in the second half of next year, Reuters news agency reported on Wednesday.
Morena Makhoana told Reuters that Biovac would ramp up production of the COVID-19 vaccine before reaching output of 100 million doses a year around early 2023.
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV